{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Standard+Dose+of+Unfractionated+Heparin",
    "query": {
      "intervention": "Standard Dose of Unfractionated Heparin"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 64,
    "total_pages": 7,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Standard+Dose+of+Unfractionated+Heparin&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-30T18:04:36.881Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05426031",
      "title": "Optimal Protamine Dosing for Heparin Reversal Following Cardiopulmonary Bypass",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Coagulation; Intravascular"
      ],
      "interventions": [
        {
          "name": "Protamine fixed dose",
          "type": "DRUG"
        },
        {
          "name": "Protamine ratio dose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Miami",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 130,
      "start_date": "2022-06-28",
      "completion_date": "2023-06-01",
      "has_results": true,
      "last_update_posted_date": "2024-08-13",
      "last_synced_at": "2026-09-30T18:04:36.881Z",
      "location_count": 2,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05426031"
    },
    {
      "nct_id": "NCT00657228",
      "title": "Intravenous Heparin as an Adjunct for the Treatment of Anaphylactic Reactions in an Emergency Department",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Anaphylaxis"
      ],
      "interventions": [
        {
          "name": "Intravenous heparin",
          "type": "DRUG"
        },
        {
          "name": "Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Missouri, Kansas City",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2009-12",
      "completion_date": "2010-12",
      "has_results": false,
      "last_update_posted_date": "2017-01-09",
      "last_synced_at": "2026-09-30T18:04:36.881Z",
      "location_count": 2,
      "location_summary": "Kansas City, Missouri",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00657228"
    },
    {
      "nct_id": "NCT04558125",
      "title": "Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pulmonary Embolism",
        "COVID"
      ],
      "interventions": [
        {
          "name": "TNKase",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Enoxaparin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cedars-Sinai Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 2,
      "start_date": "2020-09-08",
      "completion_date": "2021-08-08",
      "has_results": true,
      "last_update_posted_date": "2021-10-26",
      "last_synced_at": "2026-09-30T18:04:36.881Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04558125"
    },
    {
      "nct_id": "NCT00790335",
      "title": "Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Deep Vein Thrombosis",
        "Venous Thrombosis",
        "Postphlebitic Syndrome",
        "Venous Thromboembolism",
        "Post Thrombotic Syndrome"
      ],
      "interventions": [
        {
          "name": "Recombinant tissue plasminogen activator (rt-PA)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "16 Years to 75 Years"
      },
      "enrollment_count": 692,
      "start_date": "2009-11",
      "completion_date": "2017-01",
      "has_results": true,
      "last_update_posted_date": "2018-03-29",
      "last_synced_at": "2026-09-30T18:04:36.881Z",
      "location_count": 56,
      "location_summary": "Glendale, Arizona • Orange, California • Stanford, California + 48 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Danbury",
          "state": "Connecticut"
        },
        {
          "city": "Norwich",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00790335"
    },
    {
      "nct_id": "NCT00916669",
      "title": "A Randomized Study to Evaluate the Effect of Two Different Doses of Enoxaparin Sodium in Combination With Standard Chemotherapy in Patients With Stage Small Cell Lung Cancer (SCLC)",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "enoxaparin sodium",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2008-07",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-05-08",
      "last_synced_at": "2026-09-30T18:04:36.881Z",
      "location_count": 4,
      "location_summary": "Boston, Massachusetts • Peabody, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Peabody",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00916669"
    },
    {
      "nct_id": "NCT02970032",
      "title": "Evaluation of Anti-Xa Levels in Surgery Patients Receiving Fixed Dose Heparin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Deep-Venous Thrombosis",
        "Pulmonary Embolism",
        "Venous Thromboembolism"
      ],
      "interventions": [
        {
          "name": "Real time heparin dose adjustment",
          "type": "DRUG"
        },
        {
          "name": "Standard heparin dose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2016-11-10",
      "completion_date": "2017-12-08",
      "has_results": true,
      "last_update_posted_date": "2019-07-24",
      "last_synced_at": "2026-09-30T18:04:36.881Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02970032"
    },
    {
      "nct_id": "NCT03516656",
      "title": "Evaluation of Anti-Xa Levels in Surgery Patients Receiving Weight-based Heparin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Deep Vein Thrombosis",
        "Pulmonary Embolism",
        "Venous Thromboembolism"
      ],
      "interventions": [
        {
          "name": "Standard heparin dose",
          "type": "DRUG"
        },
        {
          "name": "Real time heparin dose adjustment",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2018-03-23",
      "completion_date": "2021-08-24",
      "has_results": false,
      "last_update_posted_date": "2023-05-17",
      "last_synced_at": "2026-09-30T18:04:36.881Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03516656"
    },
    {
      "nct_id": "NCT02234843",
      "title": "EINSTEIN Junior: Oral Rivaroxaban in Children With Venous Thrombosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Venous Thromboembolism"
      ],
      "interventions": [
        {
          "name": "Rivaroxaban (Xarelto, BAY59-7939)",
          "type": "DRUG"
        },
        {
          "name": "Standard of Care",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "Up to 17 Years"
      },
      "enrollment_count": 500,
      "start_date": "2014-11-13",
      "completion_date": "2019-01-30",
      "has_results": true,
      "last_update_posted_date": "2020-04-01",
      "last_synced_at": "2026-09-30T18:04:36.881Z",
      "location_count": 23,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 19 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02234843"
    },
    {
      "nct_id": "NCT00932100",
      "title": "A Study Assessing the REG1 Anticoagulation System Compared Heparin in Subjects With Acute Coronary Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Coronary Syndrome (ACS)"
      ],
      "interventions": [
        {
          "name": "REG1",
          "type": "DRUG"
        },
        {
          "name": "Heparin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regado Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 640,
      "start_date": "2009-07",
      "completion_date": "2011-01",
      "has_results": false,
      "last_update_posted_date": "2012-03-02",
      "last_synced_at": "2026-09-30T18:04:36.881Z",
      "location_count": 26,
      "location_summary": "Huntsville, Alabama • Sacramento, California • San Diego, California + 21 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00932100"
    },
    {
      "nct_id": "NCT02501434",
      "title": "Aneurysmal Subarachnoid Hemorrhage Trial RandOmizing Heparin",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Aneurysmal Subarachnoid Hemorrhage",
        "Neurobehavioral Manifestations",
        "Vasospasm, Intracranial",
        "Intracranial Aneurysm",
        "Heparin-induced Thrombocytopenia Type II"
      ],
      "interventions": [
        {
          "name": "Continuous Low-Dose IV Unfractionated Heparin Infusion",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Robert F. James",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 88,
      "start_date": "2016-04",
      "completion_date": "2024-01-01",
      "has_results": false,
      "last_update_posted_date": "2022-03-04",
      "last_synced_at": "2026-09-30T18:04:36.881Z",
      "location_count": 9,
      "location_summary": "New Haven, Connecticut • Gainesville, Florida • Tallahassee, Florida + 6 more",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Tallahassee",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02501434"
    }
  ]
}